KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment with Trifluridine/Tipiracil in Patients With mCRC
First proof of genomics-based precision medicine for a chemotherapy in metastatic colorectal cancer
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1586 results
Estimate of the Global Economic Cost of the Most Prevalent Cancers in 204 Countries From 2020 To 2050
Findings from an analytical modelling study
EMA Recommends Granting a Marketing Authorisation for Akeega, Fixed-Dose Combinations of Niraparib/Abiraterone Acetate
It is indicated with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer with BRCA1/2 mutations
Patient Exposure to Anticancer Drugs Subsequently Withdrawn from the FDA Accelerated Approval Programme Due to Lack of Benefit
Findings from a cross-sectional study
Neoadjuvant Followed by Adjuvant Pembrolizumab Prolongs Event-Free Survival Compared to Adjuvant Treatment Only in High-Risk, Resectable Stage III or IV Melanoma
Findings from the S1801 study
Hyperfractionated Intensity-Modulated Radiotherapy Decreases the Rate of Severe Late Complications and Improves Overall Survival in Locally Advanced Recurrent Nasopharyngeal Carcinoma
Findings from the first randomised, phase III study to compare the safety and efficacy of hyperfractionated versus standard fractionated schedule in this setting
Exposure to Antibiotics, Specifically Fluoroquinolones, Before Treatment with Immune Checkpoint Inhibitor Associated with Worse Overall Survival Among Older Adults with Cancer
Findings from a population-level cohort study
EMA Recommends Extension of Indications for Cemiplimab
New indication concerns a combination with platinum‐based chemotherapy for the first‐line treatment of NSCLC expressing PD-L1 in ≥ 1% of tumour cells, with no EGFR, ALK or ROS1 aberrations
Darolutamide Maintenance Improves Outcomes in Patients with mCRPC Who Were Previously Treated with an ARPI, and Not Progressing After Subsequent Taxane Treatment
Findings from the SAKK 08/16
EMA Recommends Granting a Marketing Authorisation for Ivosidenib
It is recommended for the treatment of newly diagnosed acute myeloid leukaemia and for the treatment of locally advanced or metastatic cholangiocarcinoma
Mediterranean Diet Associated with a Higher Probability of Response in Patients with Advanced Melanoma Treated with Immune Checkpoint Blockade
Findings from a prospective multicentre cohort study
Darolutamide in Combination with ADT and Docetaxel Increases Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Findings from post hoc subgroup analyses of the ARASENS study